Latest filing published 28 Aug 2026 for Boundless Bio, Inc., €47k. Read the official filing
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Kevin Tang across 4 companies, led by Boundless Bio, Inc., Aurinia Pharmaceuticals Inc. and Fulcrum Therapeutics, Inc. We count 42 filings; the first trade dates from 16 September 2024 and the latest from 26 August 2026.
Market trades split into 40 purchases (€34.0M) and 1 sale (€47k). The totals do not cover 10 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2026 to date brings 34 purchases and 1 sale.
Half of the purchases are above €130k and half below. Measured against the company's value, the median purchase equals 0.067% of market capitalisation, across 23 purchases where it is known. The 40 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 28 August 2026, reports an open-market sale of €47k in Boundless Bio, Inc. The clock since the last published purchase (21 July 2026) now reads 89 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 42 declarations